FT
About
Fulgent Therapeutics was issued its CLIA license (CLIA 05D2043189/CLF 00342581). Apart from traditional single gene tests, Fulgent Therapeutics has been investing heavily in the future. Using Next Generation Sequencing (NGS) technology we are developing a new series of panel based tests for our clients.
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- Temple City, US
Contact Information
Find more investors like Fulgent
Search Investors